LONG-TERM BEVACIZUMAB TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CANCER WHO ARE RECEIVING FOLFOX4 AND FOLFIRI CHEMOTHERAPY

被引：0
|
作者：
Davidenko, Irina [1 ]
Kazantseva, Margarita [2 ]
Potemin, Sergey [2 ]
Elizbaryan, Karina [2 ]
Mamaeva, Elena [2 ]
Burdik, Oksana [2 ]
机构：
[1] Krasnodar City Oncol Ctr, Krasnodar, Russia
[2] Krasnodar Oncol Ctr, Krasnodar, Russia
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：98 / 98
页数：1
相关论文
共 50 条
  • [21] Oxaliplatin, fluorouracil and leucovorin (FOLFOX4) as first line treatment in elderly patients with metastatic colorectal cancer
    Ratti, R.
    Coccorullo, Z.
    Addarno, G.
    Venturino, A.
    Colloca, G.
    Guarneri, D.
    Carnpora, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 87 - 87
  • [22] Outcomes of palliative local treatment in metastatic colorectal cancer patients receiving chemotherapy plus bevacizumab
    Ben Zhao
    Lu Wang
    Qianqian Yu
    Guangyuan Hu
    Hong Qiu
    Mingsheng Zhang
    Li Sun
    Ping Peng
    Xianglin Yuan
    OncologyandTranslationalMedicine, 2018, 4 (03) : 93 - 100
  • [23] A comparison of medical resource use for 4 chemotherapy regimens as first-line treatment for metastatic colorectal cancer (MCRC): XELOX vs. FOLFOX4 ± bevacizumab (A)
    Scheithauer, W.
    Cassidy, J.
    Figer, A.
    Wong, R.
    Koski, S.
    Lichinitser, M.
    Yang, T.
    Clarke, S.
    Diaz-Rubio, E.
    Garrison, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] Comparative study: Side effects of Folfox4 and folfiri for colorectal cancer chemotherapy regiment in Margono Soekarjo Hospital, Purwokerto
    Wiratama, I. N. A.
    Djatmiko, W.
    Ardiansyah, I. R.
    Salipi, M. B.
    Ilmi, A. F. N.
    Maharani, N.
    ANNALS OF ONCOLOGY, 2018, 29
  • [25] Adherence to the FOLFOX4 regimen in colorectal cancer patients
    Gonzalez, J.
    Gonzalez-Navarro, M.
    Albert-Mari, A.
    Lopez-Montenegro, M.
    Romero-Crespo, I.
    Jimenez-Torres, N. V.
    PHARMACY WORLD & SCIENCE, 2008, 30 (06): : 1018 - 1018
  • [26] Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
    Shui, Lin
    Wu, Yu-Shen
    Lin, Huapeng
    Shui, Pixian
    Sun, Qin
    Chen, Xiaopin
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 48 (05) : 1870 - 1881
  • [27] FOLFOX-4 versus FOLFIRI in the treatment of metastatic colorectal cancer - a prospective randomised study
    Badulescu, F.
    Badulescu, A.
    Schenker, M.
    Ionescu, M.
    Ninulescu, C.
    Crisan, A.
    Dinescu, S.
    EJC SUPPLEMENTS, 2009, 7 (02): : 349 - 349
  • [28] Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer
    Kuboki, Yasutoshi
    Mizunuma, Nobuyuki
    Ozaka, Masato
    Ogura, Mariko
    Suenaga, Mitsukuni
    Shinozaki, Eiji
    Matsusaka, Satoshi
    Chin, Keishou
    Matsuura, Masaaki
    Hatake, Kiyohiko
    ONCOLOGY LETTERS, 2011, 2 (03) : 493 - 498
  • [29] A comparison of medical resource use for xelox vs. folfox4 ± bevacizumab when administered as firstline treatment for patients with metastatic colorectal cancer(MCRC)
    Scheithauer, W.
    Cassidy, J.
    Figer, A.
    Wong, R.
    Koski, S.
    Lichinitser, M.
    Yang, T.
    Clarke, S.
    Diaz-Rubio, E.
    Garrison, L.
    ANNALS OF ONCOLOGY, 2007, 18 : VII86 - VII86
  • [30] Cost comparison of XELOX vs. FOLFOX4 ± bevacizumab as first-line treatment in patients with metastatic colorectal cancer (MCRC):: US findings
    Garrison, L.
    Cassidy, J.
    Saleh, M.
    Lee, F.
    Mena, R.
    Fuloria, J.
    Chang, V
    Ervin, R.
    Stella, P.
    Saltz, L.
    ANNALS OF ONCOLOGY, 2007, 18 : VII74 - VII74
12345